MannKind’s Insulin Afrezza Fails to Win Approval (Update4) (Bloomberg)

In: Biotechnology News

15 Mar 2010

March 15 (Bloomberg) — MannKind Corp. , the biotechnology company run by billionaire inventor Alfred Mann , failed to win approval from U.S. regulators to market its inhaled insulin drug, Afrezza, for people with diabetes.

Here is the original: 
MannKind’s Insulin Afrezza Fails to Win Approval (Update4) (Bloomberg)

Comment Form

About Biolexis

Biolexis is a premiere online resource for life sciences professionals, investors and entrepreneurs. The site offers personalized information biotechnology news and other biotechnology resources. Information is further organized by industry sector, therapeutic areas, technology focus, service orientation, and location. With Biolexis, you can: access over 5,000 biotechnology news strories and biotechnology articles. Search biotech company information, biotech news, biotech articles and biotech related press releases.

Biotech

    high tech agricultureMicrobiologists icon 3 - Stock illustrationMicrobiologists icon 2 - Stock illustrationMicrobiologists icon 1 - Stock illustrationMicrobiologists icon 4 - Stock illustrationThe Liquid-moving Thingy

Categories

Archives